The following table or figure may be downloaded to PowerPoint for personal use in teaching and presentations. This feature is available to all subscribers to the journal.

You MUST read and follow the guidelines at Request to Reproduce AJR Content if you are distributing or using AJR content beyond academic use (limited distribution, non-revenue producing, or educational purposes).

(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 7B —78-year-old man who underwent radical retropubic prostatectomy in 1999 for adenocarcinoma of prostate. He developed prostate-specific antigen (PSA) recurrence in 2001, originally treated with single Lupron injection (leuprolide acetate, TAP Pharmaceuticals), and PSA normalized. In 2003, PSA again began rising, and he was placed on Zoladex (goserelin acetate, AstraZeneca). In 2005, he again developed rising PSA and was placed on Casodex (bicalutamide, AstraZeneca). Restaging CT and bone scans were always negative. At this point, ¹¹¹In capromab pendetide (222 MBq [6 mCi] IV) scintigraphy was requested for localization of occult recurrent disease. Planar whole-torso images (not shown) showed negative findings. SPECT/CT images obtained at 96 hours after injection detect recurrence in CT-negative, normal-sized retroperitoneal interaortocaval lymph node (arrows). This case shows synergism of combined SPECT/CT.